{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:50:29Z","timestamp":1787878229517,"version":"build-2784847793"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470935"],"award-info":[{"award-number":["81470935"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370805"],"award-info":[{"award-number":["81370805"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670645"],"award-info":[{"award-number":["81670645"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12894-018-0345-4","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T13:03:33Z","timestamp":1525352613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and safety of PDE5-Is and \u03b1-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs"],"prefix":"10.1186","volume":"18","author":[{"given":"Xifeng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangqun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,3]]},"reference":[{"key":"345_CR1","first-page":"2186","volume":"11","author":"JC Nickel","year":"2004","unstructured":"Nickel JC, Saad F. The American urological association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion. Can J Urol. 2004;11:2186\u201393.","journal-title":"Can J Urol"},{"key":"345_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0090-4295(01)01506-0","volume":"59","author":"G Welch","year":"2002","unstructured":"Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the health professionals follow-up study. Urology. 2002;59:245\u201350.","journal-title":"Urology"},{"key":"345_CR3","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/j.juro.2008.03.141","volume":"179","author":"JT Wei","year":"2008","unstructured":"Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in america project: benign prostatic hyperplasia. J Urol. 2008;179:S75\u201380.","journal-title":"J Urol"},{"key":"345_CR4","first-page":"427","volume":"25","author":"J Colella","year":"2005","unstructured":"Colella J, Kochis E, Galli B, et al. Urolithiasis\/nephrolithiasis: what\u2019s it all about? Urol Nurs. 2005;25:427\u201348. 75, 49","journal-title":"Urol Nurs"},{"key":"345_CR5","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(06)69474-9","volume":"368","author":"JM Hollingsworth","year":"2006","unstructured":"Hollingsworth JM, Rogers MA, Kaufman SR, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet (London, England). 2006;368:1171\u20139.","journal-title":"Lancet (London, England)"},{"key":"345_CR6","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/iju.12496","volume":"21","author":"K Jayant","year":"2014","unstructured":"Jayant K, Agrawal R, Agrawal S. Tamsulosin versus tamsulosin plus tadalafil as medical expulsive therapy for lower ureteric stones: a randomized controlled trial. Int J Urol. 2014;21:1012\u20135.","journal-title":"Int J Urol"},{"key":"345_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2009.04.028","volume":"56","author":"M Stohrer","year":"2009","unstructured":"Stohrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56:81\u20138.","journal-title":"Eur Urol"},{"key":"345_CR8","first-page":"20","volume":"13","author":"H Lepor","year":"2011","unstructured":"Lepor H. Medical treatment of benign prostatic hyperplasia. Rev Urol. 2011;13:20\u201333.","journal-title":"Rev Urol"},{"key":"345_CR9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1464-410X.2004.04765.x","volume":"93","author":"MJ Speakman","year":"2004","unstructured":"Speakman MJ, Kirby RS, Joyce A, et al. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int. 2004;93:985\u201390.","journal-title":"BJU Int"},{"key":"345_CR10","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.eururo.2004.12.013","volume":"47","author":"RC Rosen","year":"2005","unstructured":"Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:824\u201337.","journal-title":"Eur Urol"},{"key":"345_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.eururo.2006.02.023","volume":"50","author":"F Porpiglia","year":"2006","unstructured":"Porpiglia F, Vaccino D, Billia M, et al. Corticosteroids and tamsulosin in the medical expulsive therapy for symptomatic distal ureter stones: single drug or association? Eur Urol. 2006;50:339\u201344.","journal-title":"Eur Urol"},{"key":"345_CR12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/j.1464-410X.2012.10984.x","volume":"109","author":"MG Wyllie","year":"2012","unstructured":"Wyllie MG. Monotherapy for comorbid erectile dysfunction and lower urinary tract symptoms: phosphodiesterase inhibitor or alpha-adrenoceptor antagonist? BJU Int. 2012;109:965\u20136.","journal-title":"BJU Int"},{"key":"345_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.urology.2014.09.022","volume":"85","author":"S Kumar","year":"2015","unstructured":"Kumar S, Jayant K, Agrawal MM, et al. Role of tamsulosin, tadalafil, and silodosin as the medical expulsive therapy in lower ureteric stone: a randomized trial (a pilot study). Urology. 2015;85:59\u201363.","journal-title":"Urology"},{"key":"345_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00240-006-0073-1","volume":"35","author":"C Gratzke","year":"2007","unstructured":"Gratzke C, Uckert S, Kedia G, et al. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res. 2007;35:49\u201354.","journal-title":"Urol Res"},{"key":"345_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/ijcp.12135","volume":"67","author":"U Capitanio","year":"2013","unstructured":"Capitanio U, Salonia A, Briganti A, et al. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates. Int J Clin Pract. 2013;67:544\u201351.","journal-title":"Int J Clin Pract"},{"key":"345_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","volume":"64","author":"M Oelke","year":"2013","unstructured":"Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118\u201340.","journal-title":"Eur Urol"},{"key":"345_CR17","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","volume":"61","author":"M Oelke","year":"2012","unstructured":"Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61:917\u201325.","journal-title":"Eur Urol"},{"key":"345_CR18","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.eururo.2012.02.033","volume":"61","author":"M Gacci","year":"2012","unstructured":"Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61:994\u20131003.","journal-title":"Eur Urol"},{"key":"345_CR19","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.4103\/1008-682X.154990","volume":"17","author":"XH Wang","year":"2015","unstructured":"Wang XH, Wang X, Shi MJ, et al. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and alpha-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. Asian J Androl. 2015;17:1022\u201332.","journal-title":"Asian J Androl"},{"key":"345_CR20","unstructured":"International Prospective Register of Systematic Reviews [\n                    http:\/\/www.crd.york.ac.uk\/prospero\n                    \n                  ]. Accessed 16 Mar 2017."},{"key":"345_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med. 2009;151:264\u20139. w64","journal-title":"Ann Int Med"},{"key":"345_CR22","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/sim.1184","volume":"21","author":"JA Sterne","year":"2002","unstructured":"Sterne JA, Juni P, Schulz KF, et al. Statistical methods for assessing the influence of study characteristics on treatment effects in \u2018meta-epidemiological\u2019 research. Stat Med. 2002;21:1513\u201324.","journal-title":"Stat Med"},{"key":"345_CR23","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N","volume":"15","author":"R DerSimonian","year":"1996","unstructured":"DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med. 1996;15:1237\u201348. discussion 49-52","journal-title":"Stat Med"},{"key":"345_CR24","first-page":"401","volume":"138","author":"NJ Blunch","year":"1976","unstructured":"Blunch NJ. Statistical analysis of data from clinical and retrospective studies. Ugeskr Laeger. 1976;138:401\u20137.","journal-title":"Ugeskr Laeger"},{"key":"345_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4111\/icu.2016.57.5.351","volume":"57","author":"HB Kc","year":"2016","unstructured":"Kc HB, Shrestha A, Acharya GB, et al. Tamsulosin versus tadalafil as a medical expulsive therapy for distal ureteral stones: a prospective randomized study. Investig Clin Urol. 2016;57:351\u20136.","journal-title":"Investig Clin Urol"},{"key":"345_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.eururo.2015.10.037","volume":"69","author":"S Puvvada","year":"2016","unstructured":"Puvvada S, Mylarappa P, Aggarwal K, et al. Comparative efficacy of tadalafil versus tamsulosin as the medical expulsive therapy in lower ureteric stone: a prospective randomized trial. Cent European J Urol. 2016;69:178\u201382.","journal-title":"Cent European J Urol"},{"key":"345_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4111\/kju.2014.55.3.196","volume":"55","author":"S Kumar","year":"2014","unstructured":"Kumar S, Jayant K, Agrawal S, et al. Comparative efficacy of tamsulosin versus tamsulosin with tadalafil in combination with prednisolone for the medical expulsive therapy of lower ureteric stones: a randomized trial. Korean J Urol. 2014;55:196\u2013200.","journal-title":"Korean J Urol"},{"key":"345_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11255-012-0317-7","volume":"45","author":"RP Regadas","year":"2013","unstructured":"Regadas RP, Reges R, Cerqueira JB, et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial. Int Urol Nephrol. 2013;45:39\u201343.","journal-title":"Int Urol Nephrol"},{"key":"345_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1757-5672.2011.00088.x","volume":"3","author":"SC Kim","year":"2011","unstructured":"Kim SC, Park JK, Kim SW, et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo-controlled pilot study using Tamsulosin as an active control. Low Urin Tract Symptoms. 2011;3:86\u201393.","journal-title":"Low Urin Tract Symptoms"},{"key":"345_CR30","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1111\/j.1743-6109.2008.00940.x","volume":"5","author":"A Bechara","year":"2008","unstructured":"Bechara A, Romano S, Casabe A, et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS\/BPH. Pilot study. J Sex Med. 2008;5:2170\u20138.","journal-title":"J Sex Med"},{"key":"345_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jsm.12357","volume":"11","author":"DV Singh","year":"2014","unstructured":"Singh DV, Mete UK, Mandal AK, et al. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. J Sex Med. 2014;11:187\u201396.","journal-title":"J Sex Med"},{"key":"345_CR32","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.eururo.2007.01.033","volume":"51","author":"SA Kaplan","year":"2007","unstructured":"Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51:1717\u201323.","journal-title":"Eur Urol"},{"key":"345_CR33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4103\/0974-7796.120293","volume":"5","author":"A Abolyosr","year":"2013","unstructured":"Abolyosr A, Elsagheer GA, Abdel-Kader MS, et al. Evaluation of the effect of sildenafil and\/or doxazosin on benign prostatic hyperplasia-related lower urinary tract symptoms and erectile dysfunction. Urol Ann. 2013;5:237\u201340.","journal-title":"Urol Ann"},{"key":"345_CR34","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/aja.2010.177","volume":"13","author":"Z Jin","year":"2011","unstructured":"Jin Z, Zhang ZC, Liu JH, et al. An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Asian J Androl. 2011;13:630\u20135.","journal-title":"Asian J Androl"},{"key":"345_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00345-009-0484-z","volume":"28","author":"A Tuncel","year":"2010","unstructured":"Tuncel A, Nalcacioglu V, Ener K, et al. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol. 2010;28:17\u201322.","journal-title":"World J Urol"},{"key":"345_CR36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1743-6109.2008.01109.x","volume":"6","author":"G Liguori","year":"2009","unstructured":"Liguori G, Trombetta C, De Giorgi G, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med. 2009;6:544\u201352.","journal-title":"J Sex Med"},{"key":"345_CR37","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.juro.2008.05.052","volume":"180","author":"CF Ng","year":"2008","unstructured":"Ng CF, Wong A, Cheng CW, et al. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. J Urol. 2008;180:1042\u20136.","journal-title":"J Urol"},{"key":"345_CR38","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/j.1743-6109.2012.02718.x","volume":"9","author":"M Gacci","year":"2012","unstructured":"Gacci M, Vittori G, Tosi N, et al. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9:1624\u201333.","journal-title":"J Sex Med"},{"key":"345_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/luts.12016","volume":"6","author":"S Kumar","year":"2014","unstructured":"Kumar S, Kondareddy C, Ganesamoni R, et al. Randomized controlled trial to assess the efficacy of the combination therapy of Alfuzosin and Tadalafil in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Low Urin Tract Symptoms. 2014;6:35\u201340.","journal-title":"Low Urin Tract Symptoms"},{"key":"345_CR40","doi-asserted-by":"publisher","first-page":"e28752","DOI":"10.5812\/numonthly.28752","volume":"7","author":"A Mehrazmay","year":"2015","unstructured":"Mehrazmay A, Karambakhsh A, Salesi M. Reporting quality assessment of randomized controlled trials published in nephrology urology monthly journal. Nephrourol Mon. 2015;7:e28752.","journal-title":"Nephrourol Mon"},{"key":"345_CR41","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.eururo.2012.02.033","volume":"61","author":"JQ Yuan","year":"2012","unstructured":"Yuan JQ, Yang ZY, Mao C. Re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. a systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61:994\u20131003. European urology. 2012; 62:e35; author reply e6\u20138","journal-title":"Eur Urol"},{"key":"345_CR42","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1464-410X.2010.09698.x","volume":"107","author":"HK Laydner","year":"2011","unstructured":"Laydner HK, Oliveira P, Oliveira CR, et al. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. BJU Int. 2011;107:1104\u20139.","journal-title":"BJU Int"},{"key":"345_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.urology.2010.07.508","volume":"77","author":"L Liu","year":"2011","unstructured":"Liu L, Zheng S, Han P, et al. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Urology. 2011;77:123\u20139.","journal-title":"Urology"},{"key":"345_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1743-6109.2009.01511.x","volume":"7","author":"B Fibbi","year":"2010","unstructured":"Fibbi B, Morelli A, Vignozzi L, et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med. 2010;7:59\u201369.","journal-title":"J Sex Med"},{"key":"345_CR45","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/j.1464-410X.2006.06501.x","volume":"98","author":"H Tinel","year":"2006","unstructured":"Tinel H, Stelte-Ludwig B, Hutter J, et al. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int. 2006;98:1259\u201363.","journal-title":"BJU Int"},{"key":"345_CR46","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.juro.2009.11.014","volume":"183","author":"R Dmochowski","year":"2010","unstructured":"Dmochowski R, Roehrborn C, Klise S, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol. 2010;183:1092\u20137.","journal-title":"J Urol"},{"key":"345_CR47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/sj.ijir.3900622","volume":"12","author":"M Braun","year":"2000","unstructured":"Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the \u2018Cologne male Survey\u2019. Int J Impot Res. 2000;12:305\u201311.","journal-title":"Int J Impot Res"},{"key":"345_CR48","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1046\/j.1464-410X.2003.04072.x","volume":"91","author":"M Gacci","year":"2003","unstructured":"Gacci M, Bartoletti R, Figlioli S, et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int. 2003;91:196\u2013200.","journal-title":"BJU Int"},{"key":"345_CR49","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.eururo.2003.08.015","volume":"44","author":"R Rosen","year":"2003","unstructured":"Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637\u201349.","journal-title":"Eur Urol"},{"key":"345_CR50","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1097\/01.ju.0000067940.76090.73","volume":"169","author":"G Vallancien","year":"2003","unstructured":"Vallancien G, Emberton M, Harving N, et al. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol. 2003;169:2257\u201361.","journal-title":"J Urol"},{"key":"345_CR51","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2005.12.050","volume":"49","author":"S Uckert","year":"2006","unstructured":"Uckert S, Oelke M, Stief CG, et al. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol. 2006;49:740\u20135.","journal-title":"Eur Urol"},{"key":"345_CR52","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ejphar.2014.08.005","volume":"741","author":"GT Kedia","year":"2014","unstructured":"Kedia GT, Oelke M, Sonnenberg JE, et al. Phosphodiesterase isoenzymes in the human urethra: a molecular biology and functional study. Eur J Pharmacol. 2014;741:330\u20135.","journal-title":"Eur J Pharmacol"},{"key":"345_CR53","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1046\/j.1464-410X.2002.03040.x","volume":"90","author":"K Sairam","year":"2002","unstructured":"Sairam K, Kulinskaya E, McNicholas TA, et al. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90:836\u20139.","journal-title":"BJU Int"},{"key":"345_CR54","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/pros.22686","volume":"73","author":"L Vignozzi","year":"2013","unstructured":"Vignozzi L, Gacci M, Cellai I, et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate. 2013;73:1391\u2013402.","journal-title":"Prostate"},{"key":"345_CR55","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.eururo.2012.07.025","volume":"62","author":"F Fusco","year":"2012","unstructured":"Fusco F, di Villa Bianca R, Mitidieri E, et al. Sildenafil effect on the human bladder involves the L-cysteine\/hydrogen sulfide pathway: a novel mechanism of action of phosphodiesterase type 5 inhibitors. Eur Urol. 2012;62:1174\u201380.","journal-title":"Eur Urol"},{"key":"345_CR56","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/nau.21209","volume":"31","author":"PG Cohen","year":"2012","unstructured":"Cohen PG. Intra-abdominal pressure, LUTS, and tadalafil. Re: Andersson K-E, et al. tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol urodyn 2011;30:292-301. Neurourol Urodyn. 2012;31:706.","journal-title":"Neurourol Urodyn"},{"key":"345_CR57","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.eururo.2012.09.006","volume":"63","author":"F Giuliano","year":"2013","unstructured":"Giuliano F, Uckert S, Maggi M, et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013;63:506\u201316.","journal-title":"Eur Urol"},{"key":"345_CR58","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1111\/j.1743-6109.2011.02416.x","volume":"8","author":"A Morelli","year":"2011","unstructured":"Morelli A, Sarchielli E, Comeglio P, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011;8:2746\u201360.","journal-title":"J Sex Med"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-018-0345-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-018-0345-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-018-0345-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T19:06:14Z","timestamp":1556823974000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-018-0345-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,3]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["345"],"URL":"https:\/\/doi.org\/10.1186\/s12894-018-0345-4","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,3]]},"assertion":[{"value":"9 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"30"}}